Spero Therapeutics Announces Executive Leadership Changes
The Cambridge-based company names two new executives while planning for the retirement of its veteran operating officer.
Updated on Oct. 26, 2026 in People
Live Poll
Does frequent leadership turnover at biopharmaceutical companies make you trust their long-term outlook less?
Spero Therapeutics has appointed Amy Rock as Chief Regulatory and Quality Officer and Dae Gon Ha as Senior Vice President of Corporate Development. Simultaneously, the company announced that Chief Operating Officer Timothy Keutzer will retire at the end of 2026.
Why it matters
These leadership appointments signal a strategic shift as the company focuses on advancing its immunology pipeline and the development of SP001 for IgG4-related disease. The transition helps realign the executive team to support these long-term operational objectives.
The new executive team brings significant industry depth, with Amy Rock contributing 25 years of biopharmaceutical experience and Dae Gon Ha adding nine years of industry expertise.
The players
Amy Rock
She joins Spero Therapeutics as Chief Regulatory and Quality Officer after previously serving as Senior Vice President of Regulatory Sciences at Vir Biotechnology.
Dae Gon Ha
He is the new Senior Vice President of Corporate Development, bringing experience from his previous role as Senior Vice President of Strategy and Business Development at Fulcrum Therapeutics.
Timothy Keutzer
He is retiring as Chief Operating Officer after an eleven-year tenure at the Cambridge-based biopharmaceutical firm.
The details
Timothy Keutzer, who served at Spero Therapeutics for eleven years, will see his responsibilities distributed among other executive team members following his departure. The company is actively positioning itself to expand its immunology portfolio under this updated leadership structure.
Timeline
October 26, 2026: Spero Therapeutics announced new executive appointments and a retirement.
December 31, 2026: Timothy Keutzer will retire as Chief Operating Officer.
Market Landscape
This reorganization reflects the broader industry shift toward specialized immunology R&D pipelines among growing biopharmaceutical firms. It positions Spero Therapeutics to compete more effectively as it transitions from general development to targeted disease therapies.
These administrative changes have no immediate impact on customer pricing or product availability for the average consumer. Investors and stakeholders should monitor the upcoming transition as it impacts the execution of the company's long-term immunology drug development.
The takeaway
Companies frequently restructure their leadership teams during significant shifts in drug development pipelines to ensure the necessary expertise is present. This transition marks a planned evolution for Spero Therapeutics as it moves toward a more specialized focus on immunology.
Further reading
For more updates on executive transitions in the biotech sector, visit the People section.
Live Poll
Does frequent leadership turnover at biopharmaceutical companies make you trust their long-term outlook less?
